Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | HTR1D | P28221 | 3/20 | 0.36 |
| ▸ | HTR1B | P28222 | 3/20 | 0.36 |
| ▸ | HTR1F | P30939 | 3/20 | 0.36 |
| ▸ | HTR7 | P34969 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | HTR1E | P28566 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156887 | 0.88 | HTR6 (0.41) | HTR6HTR2CSLC6A4HTR1ADRD2 | |
| SCHEMBL1156172 | 0.86 | HTR6 (0.44) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL1156759 | 0.85 | HTR6 (0.39) | HTR6HTR2CSLC6A4HTR1ADRD2 | |
| SCHEMBL1156913 | 0.80 | HTR6 (0.38) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL1156577 | 0.77 | HTR6 (0.40) | HTR6HTR2CSLC6A4HTR1ADRD2 | |
| SCHEMBL1157164 | 0.76 | HTR2C (0.42) | HTR6HTR2CSLC6A4TNF | |
| SCHEMBL2412417 | 0.74 | HTR2C (0.35) | HTR6HTR2CSLC6A4TNFSF11 | |
| SCHEMBL2407583 | 0.73 | SOS1 (0.36) | HTR6HTR2CSLC6A4TNFSF11 | |
| SCHEMBL1156621 | 0.73 | HTR2C (0.42) | HTR6HTR2CSLC6A4HTR1ADRD2 | |
| SCHEMBL1157173 | 0.73 | HTR6 (0.46) | HTR6HTR1ADRD2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048909-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028476-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | HTR6 1412/4885HTR2C 924/4885SLC6A4 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.